United Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell UTHR and other ETFs, options, and stocks.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.

CEO

Martine A. Rothblatt

CEOMartine A. Rothblatt

Employees

1,168

Employees1,168

Headquarters

Silver Spring, Maryland

HeadquartersSilver Spring, Maryland

Founded

1996

Founded1996

Employees

1,168

Employees1,168

UTHR Key Statistics

Market cap

12.21B

Market cap12.21B

Price-Earnings ratio

12.88

Price-Earnings ratio12.88

Dividend yield

—

Dividend yield—

Average volume

612.56K

Average volume612.56K

High today

$259.94

High today$259.94

Low today

$254.06

Low today$254.06

Open price

$255.10

Open price$255.10

Volume

184.77K

Volume184.77K

52 Week high

$261.54

52 Week high$261.54

52 Week low

$204.44

52 Week low$204.44

UTHR News

Benzinga 2h

The Latest Analyst Ratings For United Therapeutics - United Therapeutics - Benzinga

Loading... Loading... Throughout the last three months, 7 analysts have evaluated United Therapeutics UTHR, offering a diverse set of opinions from bullish to...

Yahoo Finance 10h

Decoding United Therapeutics Corp: A Strategic SWOT Insight - Yahoo Finance

United Therapeutics Corp showcases robust revenue growth and solid operational performance. Specialized focus on pulmonary arterial hypertension (PAH) treatmen...

Reuters 11h

Q1 2024 United Therapeutics Corp Earnings Call

Participants Dewey Steadman; Head of IR; United Therapeutics Corporation James C. Edgemond; CFO & Treasurer; United Therapeutics Corporation Leigh Peterson;...

Analyst ratings

76%

of 17 ratings

Buy

76.5%

Hold

17.6%

Sell

5.9%

More UTHR News

Benzinga 19h

Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity

Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity On Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) reported fi...

TipRanks 1d

United Therapeutics reports Q1 EPS $6.17, consensus $5.65

Reports Q1 revenue $677.7M, consensus $623.97M. “Q1 represents another quarter of record revenue and double-digit year-over-year revenue growth,” jointly said C...